Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors.

Harney AS, Karagiannis GS, Pignatelli J, Smith BD, Kadioglu E, Wise SC, Hood MM, Kaufman MD, Leary CB, Lu WP, Al-Ani G, Chen X, Entenberg D, Oktay MH, Wang Y, Chun L, De Palma M, Jones JG, Flynn DL, Condeelis JS.

Mol Cancer Ther. 2017 Nov;16(11):2486-2501. doi: 10.1158/1535-7163.MCT-17-0241. Epub 2017 Aug 24.

PMID:
28838996
2.

A suspected delayed hemolytic transfusion reaction mediated by anti-Joa.

Jajosky RP, Lumm WC, Wise SC, Bollag RJ, Shikle JF.

Immunohematology. 2017 Jun;33(2):73-75.

PMID:
28657766
3.

Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia.

Cortes J, Talpaz M, Smith HP, Snyder DS, Khoury J, Bhalla KN, Pinilla-Ibarz J, Larson R, Mitchell D, Wise SC, Rutkoski TJ, Smith BD, Flynn DL, Kantarjian HM, Rosen O, Van Etten RA.

Haematologica. 2017 Mar;102(3):519-528. doi: 10.3324/haematol.2016.152710. Epub 2016 Dec 7.

4.

Surgical salvage of recurrent vestibular schwannoma following prior stereotactic radiosurgery.

Wise SC, Carlson ML, Tveiten ØV, Driscoll CL, Myrseth E, Lund-Johansen M, Link MJ.

Laryngoscope. 2016 Nov;126(11):2580-2586. doi: 10.1002/lary.25943. Epub 2016 Apr 23.

PMID:
27107262
5.

Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2.

Smith BD, Kaufman MD, Leary CB, Turner BA, Wise SC, Ahn YM, Booth RJ, Caldwell TM, Ensinger CL, Hood MM, Lu WP, Patt TW, Patt WC, Rutkoski TJ, Samarakoon T, Telikepalli H, Vogeti L, Vogeti S, Yates KM, Chun L, Stewart LJ, Clare M, Flynn DL.

Mol Cancer Ther. 2015 Sep;14(9):2023-34. doi: 10.1158/1535-7163.MCT-14-1105. Epub 2015 Aug 18.

6.

Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.

Henry JR, Kaufman MD, Peng SB, Ahn YM, Caldwell TM, Vogeti L, Telikepalli H, Lu WP, Hood MM, Rutkoski TJ, Smith BD, Vogeti S, Miller D, Wise SC, Chun L, Zhang X, Zhang Y, Kays L, Hipskind PA, Wrobleski AD, Lobb KL, Clay JM, Cohen JD, Walgren JL, McCann D, Patel P, Clawson DK, Guo S, Manglicmot D, Groshong C, Logan C, Starling JJ, Flynn DL.

J Med Chem. 2015 May 28;58(10):4165-79. doi: 10.1021/acs.jmedchem.5b00067. Epub 2015 May 12.

PMID:
25965804
7.

HSP90 Inhibitor SNX5422/2112 Targets the Dysregulated Signal and Transcription Factor Network and Malignant Phenotype of Head and Neck Squamous Cell Carcinoma.

Friedman JA, Wise SC, Hu M, Gouveia C, Vander Broek R, Freudlsperger C, Kannabiran VR, Arun P, Mitchell JB, Chen Z, Van Waes C.

Transl Oncol. 2013 Aug 1;6(4):429-41. Print 2013 Aug.

8.

Paroxysmal cold hemoglobinuria: a case report.

Wise SC, Tinsley SH, Cook LO.

Immunohematology. 2012;28(4):118-23.

PMID:
23421540
9.

Targeting the KIT activating switch control pocket: a novel mechanism to inhibit neoplastic mast cell proliferation and mast cell activation.

Bai Y, Bandara G, Ching Chan E, Maric I, Simakova O, Bandara SN, Lu WP, Wise SC, Flynn DL, Metcalfe DD, Gilfillan AM, Wilson TM.

Leukemia. 2013 Feb;27(2):278-85. doi: 10.1038/leu.2012.218. Epub 2012 Jul 31. Review.

10.

The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile.

Eide CA, Adrian LT, Tyner JW, Mac Partlin M, Anderson DJ, Wise SC, Smith BD, Petillo PA, Flynn DL, Deininger MW, O'Hare T, Druker BJ.

Cancer Res. 2011 May 1;71(9):3189-95. doi: 10.1158/0008-5472.CAN-10-3224. Epub 2011 Apr 19.

11.

Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036.

Chan WW, Wise SC, Kaufman MD, Ahn YM, Ensinger CL, Haack T, Hood MM, Jones J, Lord JW, Lu WP, Miller D, Patt WC, Smith BD, Petillo PA, Rutkoski TJ, Telikepalli H, Vogeti L, Yao T, Chun L, Clark R, Evangelista P, Gavrilescu LC, Lazarides K, Zaleskas VM, Stewart LJ, Van Etten RA, Flynn DL.

Cancer Cell. 2011 Apr 12;19(4):556-68. doi: 10.1016/j.ccr.2011.03.003.

12.

AXL regulates mesothelioma proliferation and invasiveness.

Ou WB, Corson JM, Flynn DL, Lu WP, Wise SC, Bueno R, Sugarbaker DJ, Fletcher JA.

Oncogene. 2011 Apr 7;30(14):1643-52. doi: 10.1038/onc.2010.555. Epub 2010 Dec 6.

PMID:
21132014
13.

Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region.

Ahn YM, Clare M, Ensinger CL, Hood MM, Lord JW, Lu WP, Miller DF, Patt WC, Smith BD, Vogeti L, Kaufman MD, Petillo PA, Wise SC, Abendroth J, Chun L, Clark R, Feese M, Kim H, Stewart L, Flynn DL.

Bioorg Med Chem Lett. 2010 Oct 1;20(19):5793-8. doi: 10.1016/j.bmcl.2010.07.134. Epub 2010 Aug 3.

PMID:
20800479
14.

Examination of edge effects with different storage conditions of preplated dimethyl sulfoxide nanospots in ChemLib 1,536- and 3,456-well assay-ready plates.

Turner BA, Evans BP, Pearson TT, Braden TK, Wise SC.

Assay Drug Dev Technol. 2008 Dec;6(6):811-8. doi: 10.1089/adt.2008.169.

15.
16.

Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone.

Camp HS, Li O, Wise SC, Hong YH, Frankowski CL, Shen X, Vanbogelen R, Leff T.

Diabetes. 2000 Apr;49(4):539-47.

PMID:
10871190
17.

cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype.

Smith LM, Wise SC, Hendricks DT, Sabichi AL, Bos T, Reddy P, Brown PH, Birrer MJ.

Oncogene. 1999 Oct 28;18(44):6063-70.

19.

Identification of domains of c-Jun mediating androgen receptor transactivation.

Wise SC, Burmeister LA, Zhou XF, Bubulya A, Oberfield JL, Birrer MJ, Shemshedini L.

Oncogene. 1998 Apr 16;16(15):2001-9.

20.
21.

c-Jun can mediate androgen receptor-induced transactivation.

Bubulya A, Wise SC, Shen XQ, Burmeister LA, Shemshedini L.

J Biol Chem. 1996 Oct 4;271(40):24583-9.

22.

Dominant-negative mutants of cJun inhibit AP-1 activity through multiple mechanisms and with different potencies.

Brown PH, Kim SH, Wise SC, Sabichi AL, Birrer MJ.

Cell Growth Differ. 1996 Aug;7(8):1013-21.

Supplemental Content

Support Center